The psoriatic arthritis therapeutics market size is expected to grow from USD 10.55 billion in 2025 to USD 11.16 billion in 2026 and is forecast to reach USD 14.74 billion by 2031 at 5.74% CAGR over 2026-2031. This report is Segmented by Drug Class (NSAIDs, Biologic DMARDs, and More), Route of Administration (Oral, Parenteral, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Age Group (Adults, Pediatric, and Geriatric) and Geography (North America, Europe, Asia-Pacific, and More). The Market and Forecasts are Provided in Terms of Value (USD).
Cost-sensitive prescribers are cycling more patients to methotrexate plus targeted synthetics before initiating injectable biologics, creating an opportunity for hybrid sequencing strategies. Adalimumab biosimilars captured 23% of United States anti-TNF volume by late 2024 and stimulated parallel adoption in Europe, where tender purchasing amplifies price erosion. This competitive dynamic has pushed originators to pivot toward next-generation assets, such as guselkumab and risankizumab, that offer distinct mechanisms or improved dosing convenience.
Injectables retained 71.83% revenue share thanks to high-dose bioavailability requirements for monoclonal antibodies. Subcutaneous self-dosing every eight to twelve weeks improves adherence compared with weekly regimens, supporting sustained parenteral demand. Nevertheless, oral products delivered the fastest growth at 6.72% CAGR and could elevate their psoriatic arthritis therapeutics market size to USD 3.39 billion by 2031.
JAK and TYK2 inhibitors, including tofacitinib and deucravacitinib, are central to this shift, allowing rheumatologists to initiate therapy without injection-training infrastructure. Head-to-head trials show similar efficacy to subcutaneous comparators, with survey data indicating 78% of patients would prefer oral dosing if safety and efficacy are equivalent.
Asia-Pacific posted the fastest 6.9% CAGR and could overtake Europe by 2031. Japan already treats 55.3% of psoriatic arthritis cases with biologics following guideline revisions that prioritize early intensive therapy. China and India are scaling domestic biosimilar production, trimming unit costs and making advanced care more attainable for urban middle-class populations. South Korea’s single-payer model funds risankizumab and guselkumab after managed-entry agreements that cap budget impact.
Europe’s steady growth rests on health-technology assessments that weigh clinical benefit against price, accelerating biosimilar penetration for cost containment. Outcomes-based contracts in Germany and France tie reimbursement to real-world PASI and ACR responses, influencing global price-setting strategies. Latin American markets lag owing to specialist shortages and funding constraints, yet public-private partnerships in Brazil and Argentina are expanding rheumatology clinics and subsidizing targeted agents.
Global Psoriatic Arthritis Therapeutics Market Trends and Insights
Growing prevalence linked to obesity & metabolic syndrome
Obesity heightens psoriatic arthritis risk by 40-60%, and more than one-quarter of adults in high-income countries now meet metabolic-syndrome criteria, fueling sustained demand for biologic DMARDs. Adipose-derived cytokines amplify systemic inflammation, prompting earlier rheumatology referrals. Commercial payers increasingly acknowledge the comorbidity burden, widening coverage for advanced therapies that can reduce long-term disability costs.Expansion of approved biologic & tsDMARD therapies
Bimekizumab’s 2024 approval delivered the first dual IL-17A/F approach and posted superior skin clearance versus ixekizumab, broadening cytokine-specific choices. Phase 3 success for deucravacitinib in March 2025 (54.2% ACR20 versus 39.4% placebo) signals a new oral option that may expand first-line use in moderate disease. Rapid label additions reduce reliance on TNF inhibitors and enable sequence-based regimens tailored to biomarker profiles.High total cost of care & patient OOP burden
Annual therapy costs span USD 45,000-80,000, with Medicare beneficiaries facing USD 4,423-6,950 out-of-pocket payments that drive 15-20% discontinuation rates. Step-therapy mandates delay biologic start by 3-6 months, increasing irreversible joint damage risk.Other drivers and restraints analyzed in the detailed report include:
- Earlier diagnosis via imaging & biomarker panels
- Payer acceptance of value-based contracts
- Long-term immunosuppression safety concerns
Segment Analysis
Biologic DMARDs contributed USD 4.93 billion in 2025 and represented 46.72% of psoriatic arthritis therapeutics market share. Ustekinumab biosimilar approvals in early 2025 have already trimmed originator sales and are expected to lower brand pricing across the class. Meanwhile, non-biologic DMARDs are set to outpace at a 6.68% CAGR to 2031 as oral small molecules such as deucravacitinib expand adoption.Cost-sensitive prescribers are cycling more patients to methotrexate plus targeted synthetics before initiating injectable biologics, creating an opportunity for hybrid sequencing strategies. Adalimumab biosimilars captured 23% of United States anti-TNF volume by late 2024 and stimulated parallel adoption in Europe, where tender purchasing amplifies price erosion. This competitive dynamic has pushed originators to pivot toward next-generation assets, such as guselkumab and risankizumab, that offer distinct mechanisms or improved dosing convenience.
Injectables retained 71.83% revenue share thanks to high-dose bioavailability requirements for monoclonal antibodies. Subcutaneous self-dosing every eight to twelve weeks improves adherence compared with weekly regimens, supporting sustained parenteral demand. Nevertheless, oral products delivered the fastest growth at 6.72% CAGR and could elevate their psoriatic arthritis therapeutics market size to USD 3.39 billion by 2031.
JAK and TYK2 inhibitors, including tofacitinib and deucravacitinib, are central to this shift, allowing rheumatologists to initiate therapy without injection-training infrastructure. Head-to-head trials show similar efficacy to subcutaneous comparators, with survey data indicating 78% of patients would prefer oral dosing if safety and efficacy are equivalent.
Complete Report Scope:
- By Drug Class
- NSAIDs
- Non-Biologic DMARDs
- Biologic DMARDs
- Immunosuppressants
- Other Drug Classes
- By Route of Administration
- Oral
- Parenteral
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Age Group
- Adults
- Geriatric
- Pediatric
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America retained leadership with USD 4.37 billion sales in 2025 and 41.45% psoriatic arthritis therapeutics market share. Early FDA approvals, high biologic penetration, and mature specialty pharmacy networks offset access friction from prior-authorization delays. Medicare patients still face USD 4,423-6,950 average annual out-of-pocket spending, driving discontinuation and prompting policy debates over Part D redesign. Step-therapy protocols, while intended to control spending, may postpone optimal therapy, leading to functional decline and heightened downstream costs.Asia-Pacific posted the fastest 6.9% CAGR and could overtake Europe by 2031. Japan already treats 55.3% of psoriatic arthritis cases with biologics following guideline revisions that prioritize early intensive therapy. China and India are scaling domestic biosimilar production, trimming unit costs and making advanced care more attainable for urban middle-class populations. South Korea’s single-payer model funds risankizumab and guselkumab after managed-entry agreements that cap budget impact.
Europe’s steady growth rests on health-technology assessments that weigh clinical benefit against price, accelerating biosimilar penetration for cost containment. Outcomes-based contracts in Germany and France tie reimbursement to real-world PASI and ACR responses, influencing global price-setting strategies. Latin American markets lag owing to specialist shortages and funding constraints, yet public-private partnerships in Brazil and Argentina are expanding rheumatology clinics and subsidizing targeted agents.
List of Companies Covered in this Report:
- Abbvie
- Pfizer
- Johnson & Johnson
- Bristol-Myers Squibb
- UCB
- Eli Lilly and Company
- Amgen
- Novartis
- Sanofi
- Eisai
- Otsuka Pharmaceutical Co.
- Sumitomo Pharma Co.
- Teva Pharmaceutical Industries
- Alvotech
- Coherus BioSciences
- Galapagos NV
- Sun Pharmaceuticals Industries
- Horizon Therapeutics
- Biogen
- Samsung Bioepis
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size & Growth Forecasts (Value, USD)
6 Competitive Landscape
7 Market Opportunities & Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc.
- Pfizer Inc.
- Johnson & Johnson (Janssen)
- Bristol-Myers Squibb
- UCB S.A.
- Eli Lilly and Company
- Amgen Inc.
- Novartis AG
- Sanofi S.A.
- Eisai Co., Ltd.
- Otsuka Pharmaceutical Co.
- Sumitomo Pharma Co.
- Teva Pharmaceutical Industries
- Alvotech
- Coherus BioSciences
- Galapagos NV
- Sun Pharma
- Horizon Therapeutics
- Biogen Inc.
- Samsung Bioepis
